Han and colleagues [197] showed that treatment with the PPAR-γ agonist rosiglitazone, improves long-term white matter integrity after cerebral ischemia, at least, in part, by promoting oligodendrogenesis and facilitating microglial polarization toward the beneficial M2 phenotype. This evidence concerns the gene PPARG and brain ischemia.